Beau Batton1, Lei Li2, Nancy S Newman3, Abhik Das4, Kristi L Watterberg5, Bradley A Yoder6, Roger G Faix6, Matthew M Laughon7, Barbara J Stoll8, Rosemary D Higgins9, Michele C Walsh3. 1. Department of Pediatrics, Rainbow Babies & Children's Hospital, Case Western Reserve University, Cleveland, Ohio, USA Department of Pediatrics, Southern Illinois University School of Medicine, Springfield, Illinois, USA. 2. Statistics & Epidemiology Unit, RTI International, Research Triangle Park, Raleigh, North Carolina, USA. 3. Department of Pediatrics, Rainbow Babies & Children's Hospital, Case Western Reserve University, Cleveland, Ohio, USA. 4. Statistics & Epidemiology Unit, RTI International, Rockville, Maryland, USA. 5. Department of Pediatrics, University of New Mexico Health Sciences Center, Albuquerque, New Mexico, USA. 6. Division of Neonatology, Department of Pediatrics, University of Utah School of Medicine, Salt Lake City, Utah, USA. 7. Department of Pediatrics, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA. 8. Department of Pediatrics, Emory University School of Medicine & Children's Healthcare of Atlanta, Atlanta, Georgia, USA. 9. Eunice Kennedy Shriver National Institute of Child Health & Human Development, National Institutes of Health, Bethesda, Maryland, USA.
Abstract
OBJECTIVE: To investigate the relationships between early blood pressure (BP) changes, receipt of antihypotensive therapy and 18-22 months' corrected age (CA) outcomes for extremely preterm infants. DESIGN: Prospective observational study of infants 23(0/7)-26(6/7) weeks' gestational age (GA). Hourly BP values and antihypotensive therapy exposure in the first 24 h were recorded. Four groups were defined: infants who did or did not receive antihypotensive therapy in whom BP did or did not rise at the expected rate (defined as an increase in the mean arterial BP of ≥5 mm Hg/day). Random-intercept logistic modelling controlling for centre clustering, GA and illness severity was used to investigate the relationship between BP, antihypotensive therapies and infant outcomes. SETTING: Sixteen academic centres of the Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network. MAIN OUTCOME MEASURES: Death or neurodevelopmental impairment/developmental delay (NIDD) at 18-22 months' CA. RESULTS: Of 367 infants, 203 (55%) received an antihypotensive therapy, 272 (74%) survived to discharge and 331 (90%) had a known outcome at 18-22 months' CA. With logistic regression, there was an increased risk of death/NIDD with antihypotensive therapy versus no treatment (OR 1.836, 95% CI 1.092 to 3.086), but not NIDD alone (OR 1.53, 95% CI 0.708 to 3.307). CONCLUSIONS: Independent of early BP changes, antihypotensive therapy exposure was associated with an increased risk of death/NIDD at 18-22 months' CA when controlling for risk factors known to affect survival and neurodevelopment. CLINICAL TRIAL REGISTRATION NUMBER: clinicaltrials.gov #NCT00874393. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
OBJECTIVE: To investigate the relationships between early blood pressure (BP) changes, receipt of antihypotensive therapy and 18-22 months' corrected age (CA) outcomes for extremely preterm infants. DESIGN: Prospective observational study of infants 23(0/7)-26(6/7) weeks' gestational age (GA). Hourly BP values and antihypotensive therapy exposure in the first 24 h were recorded. Four groups were defined: infants who did or did not receive antihypotensive therapy in whom BP did or did not rise at the expected rate (defined as an increase in the mean arterial BP of ≥5 mm Hg/day). Random-intercept logistic modelling controlling for centre clustering, GA and illness severity was used to investigate the relationship between BP, antihypotensive therapies and infant outcomes. SETTING: Sixteen academic centres of the Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network. MAIN OUTCOME MEASURES: Death or neurodevelopmental impairment/developmental delay (NIDD) at 18-22 months' CA. RESULTS: Of 367 infants, 203 (55%) received an antihypotensive therapy, 272 (74%) survived to discharge and 331 (90%) had a known outcome at 18-22 months' CA. With logistic regression, there was an increased risk of death/NIDD with antihypotensive therapy versus no treatment (OR 1.836, 95% CI 1.092 to 3.086), but not NIDD alone (OR 1.53, 95% CI 0.708 to 3.307). CONCLUSIONS: Independent of early BP changes, antihypotensive therapy exposure was associated with an increased risk of death/NIDD at 18-22 months' CA when controlling for risk factors known to affect survival and neurodevelopment. CLINICAL TRIAL REGISTRATION NUMBER: clinicaltrials.gov #NCT00874393. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
Authors: Beau Batton; Lei Li; Nancy S Newman; Abhik Das; Kristi L Watterberg; Bradley A Yoder; Roger G Faix; Matthew M Laughon; Barbara J Stoll; Krisa P Van Meurs; Waldemar A Carlo; Brenda B Poindexter; Edward F Bell; Pablo J Sánchez; Richard A Ehrenkranz; Ronald N Goldberg; Abbot R Laptook; Kathleen A Kennedy; Ivan D Frantz; Seetha Shankaran; Kurt Schibler; Rosemary D Higgins; Michele C Walsh Journal: Pediatrics Date: 2013-05-06 Impact factor: 7.124
Authors: Elisabeth M W Kooi; Michelle E van der Laan; Elise A Verhagen; Koenraad N J A Van Braeckel; Arend F Bos Journal: Neonatology Date: 2013-03-26 Impact factor: 4.035
Authors: Thomas Alderliesten; Petra M A Lemmers; Ingrid C van Haastert; Linda S de Vries; Hilde J C Bonestroo; Willem Baerts; Frank van Bel Journal: J Pediatr Date: 2014-01-28 Impact factor: 4.406
Authors: J Wells Logan; T Michael O'Shea; Elizabeth N Allred; Matthew M Laughon; Carl L Bose; Olaf Dammann; Daniel G Batton; Stephen C Engelke; Alan Leviton Journal: Arch Dis Child Fetal Neonatal Ed Date: 2010-12-07 Impact factor: 5.747
Authors: Beau J Batton; Lei Li; Nancy S Newman; Abhik Das; Kristi L Watterberg; Bradley A Yoder; Roger G Faix; Matthew M Laughon; Krisa P Van Meurs; Waldemar A Carlo; Rosemary D Higgins; Michele C Walsh Journal: J Pediatr Date: 2012-02-14 Impact factor: 4.406
Authors: E M Dempsey; K J Barrington; N Marlow; C P O'Donnell; J Miletin; G Naulaers; P-Y Cheung; D Corcoran; G Pons; Z Stranak; D Van Laere Journal: Neonatology Date: 2014-02-27 Impact factor: 4.035
Authors: B Batton; L Li; N S Newman; A Das; K L Watterberg; B A Yoder; R G Faix; M M Laughon; B J Stoll; R D Higgins; M C Walsh Journal: J Perinatol Date: 2014-02-06 Impact factor: 2.521
Authors: Yvonne A Eiby; Nicole Y Shrimpton; Ian M R Wright; Eugenie R Lumbers; Paul B Colditz; Greg J Duncombe; Barbara E Lingwood Journal: J Physiol Date: 2018-07-02 Impact factor: 5.182
Authors: Yvonne A Eiby; Nicole Y Shrimpton; Ian M R Wright; Eugenie R Lumbers; Paul B Colditz; Greg J Duncombe; Barbara E Lingwood Journal: Pediatr Res Date: 2016-08-04 Impact factor: 3.756
Authors: Ningxin Luo; Siyuan Jiang; Patrick J McNamara; Xiaoying Li; Yan Guo; Yang Wang; Junyan Han; Yingping Deng; Yi Yang; Shoo K Lee; Yun Cao Journal: Front Pediatr Date: 2021-04-22 Impact factor: 3.418
Authors: Laura E Miller; Matthew M Laughon; Reese H Clark; Kanecia O Zimmerman; Christoph P Hornik; Samia Aleem; P Brian Smith; Rachel G Greenberg Journal: J Perinatol Date: 2021-03-23 Impact factor: 3.225
Authors: Neha Kumbhat; Barry Eggleston; Alexis S Davis; Krisa P Van Meurs; Sara Bonamo DeMauro; Elizabeth E Foglia; Satyanarayan Lakshminrusimha; Michele C Walsh; Kristi L Watterberg; Myra H Wyckoff; Abhik Das; Sara C Handley Journal: Arch Dis Child Fetal Neonatal Ed Date: 2020-07-30 Impact factor: 5.747